Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06060613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06060613
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Obsidian Therapeutics, Inc.
- Industry
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Interventions
- OBX-115 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2023
- Primary completion
- Jun 29, 2029
- Completion
- Jun 29, 2029
- Last update posted
- Apr 30, 2026
2023 – 2029
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute (Melanoma) | Los Angeles | California | 90025 | Recruiting |
| USC Norris Comprehensive Cancer Center (Melanoma/NSCLC) | Los Angeles | California | 90033 | Recruiting |
| Stanford Cancer Institute (Melanoma/NSCLC) | Stanford | California | 94305 | Recruiting |
| Orlando Health Cancer Institute (Melanoma/NSCLC) | Orlando | Florida | 32806 | Recruiting |
| James Graham Brown Cancer Center (Melanoma/NSCLC) | Louisville | Kentucky | 40202 | Recruiting |
| Memorial Sloan Kettering (Melanoma/NSCLC) | New York | New York | 10065 | Recruiting |
| The Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| Allegheny Research Institute (Melanoma/NSCLC) | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| M.D. Anderson Cancer Center (Melanoma/NSCLC) | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06060613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06060613 live on ClinicalTrials.gov.